Unveiling the Potential of BenzylethyleneAryl-Urea Scaffolds for the Design of New Onco Immunomodulating Agents.
CD-11b
CD-80
HT-29
PD-L1
THP-1
VEGFR-2
angiogenesis
aryl urea
co-cultures
immune checkpoints
tumor microenvironment
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
29 May 2023
29 May 2023
Historique:
received:
24
04
2023
revised:
08
05
2023
accepted:
25
05
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
This work focuses on the development of thirteen benzylethylenearyl ureas and one carbamate. After the synthesis and purification of the compounds, we studied their antiproliferative action on cell lines, such as HEK-293, and cancer ones, such as HT-29, MCF-7 or A-549, on the immune Jurkat T-cells and endothelial cells HMEC-1. Compounds
Identifiants
pubmed: 37375756
pii: ph16060808
doi: 10.3390/ph16060808
pmc: PMC10302582
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministry of Economy, Industry and Competitiveness
ID : RTI2018-097345-B-I00
Organisme : Ministry of Economy, Industry and Competitiveness
ID : PID2021-1267770B-100
Organisme : Jaume I University
ID : UJI-B2021-46
Organisme : Asociación Española Contra el Cáncer
ID : PRDCA18002CARD
Références
Int J Mol Sci. 2023 Jan 30;24(3):
pubmed: 36768935
Cell Commun Signal. 2022 Apr 7;20(1):49
pubmed: 35392964
PLoS One. 2018 Feb 20;13(2):e0192958
pubmed: 29462209
Cancers (Basel). 2022 Jan 27;14(3):
pubmed: 35158916
Int J Mol Sci. 2019 Feb 15;20(4):
pubmed: 30781344
Eur J Med Chem. 2019 Jan 15;162:781-792
pubmed: 30502686
Pharmaceuticals (Basel). 2023 Feb 13;16(2):
pubmed: 37259426
Arch Razi Inst. 2021 Sep 01;76(3):659-666
pubmed: 34824758
Pharmaceuticals (Basel). 2021 Apr 06;14(4):
pubmed: 33917617
Int J Mol Sci. 2022 Jun 24;23(13):
pubmed: 35806053
Cells. 2020 Jun 24;9(6):
pubmed: 32599709
Signal Transduct Target Ther. 2020 Aug 25;5(1):166
pubmed: 32843638
F1000Prime Rep. 2014 Mar 03;6:13
pubmed: 24669294
J Exp Clin Cancer Res. 2022 Feb 19;41(1):68
pubmed: 35183252
Expert Opin Pharmacother. 2010 Aug;11(11):1943-55
pubmed: 20586710
Oncogene. 2008 Oct 6;27(45):5904-12
pubmed: 18836471
Eur J Med Chem. 2019 May 15;170:87-98
pubmed: 30878834
Cancer Res. 2012 Apr 15;72(8):1909-14
pubmed: 22508695
Cell Commun Signal. 2020 Apr 7;18(1):59
pubmed: 32264958
Mol Med Rep. 2016 Dec;14(6):5148-5154
pubmed: 27779676
Nat Rev Cancer. 2003 Jun;3(6):401-10
pubmed: 12778130
Nat Rev Drug Discov. 2022 Nov;21(11):799-820
pubmed: 35974096
J Biol Chem. 1998 Jan 9;273(2):744-8
pubmed: 9422726